Stocks
NeOnc Technologies Holdings, Inc.NTHI
NASDAQHealthcareBiotechnology$2.90
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing precision oncology therapies, including intranasal and intravenous delivery systems for brain cancer treatments. Its lead candidate, NEO100, is in clinical trials for recurrent glioblastoma, a market with high unmet need. Investors track NTHI for its potential to address brain cancers that are difficult to treat with existing drugs.
52W Range: $2.50-$12.00
Congressional Interest in NeOnc Technologies Holdings, Inc. (NTHI)
No congressional trades have been disclosed for NeOnc Technologies Holdings, Inc. (NTHI) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading NTHI?
No congressional trades found for this stock.